Dicerna Pharmaceuticals, Inc. (DRNA)

Oncology Corporate Profile

Stock Performance

2.6700
0.0000

HQ Location

480 Arsenal Street, Building 1, Suite 120
Watertown, MA 02472

Company Description

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Website: http://www.dicerna.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DCR-MYCRNAi therapeuticHepatocellular carcinoma (HCC)I
DCR-MYCRNAi therapeuticVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.dicerna.com

Recent News Headlines

Dicerna Pharmaceuticals to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference

3/27/2017 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at 3:00 p.m.

Dicerna to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on March 30, 2017

3/23/2017 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company will release its fourth quarter and full year 2016 financial results after market close on Thursday, March 30, 2017.

Dicerna to Present at Cowen and Company 37th Annual Health Care Conference

3/1/2017 09:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017, at 8:00 a.m.

Dicerna to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

2/8/2017 09:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017, at 10:30 a.m.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2/2/2017 09:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that on January 31, 2017, the Compensation Committee of the Company's Board of Directors approved the grant of an inducement stock option to purchase a total of 75,000 shares of common stock to one new employee, with a grant date of January 31, 2017 .

Dicerna to Present at the Stifel 2016 Healthcare Conference

11/9/2016 09:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016, from 3:45-4:25 p.m.

Dicerna Reports Third Quarter 2016 Financial and Operational Results

11/7/2016 09:01 pm

[at noodls] - November 7, 2016 Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference ...

Dicerna Reports Third Quarter 2016 Financial and Operational Results

11/7/2016 09:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today reported financial and operational results for the third quarter ended September 30, 2016.

Dicerna to Report Third Quarter 2016 Financial Results and Host Conference Call on November 7, 2016

10/31/2016 08:02 pm

[at noodls] - October 31, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the ...

Dicerna to Report Third Quarter 2016 Financial Results and Host Conference Call on November 7, 2016

10/31/2016 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that the Company will release its third quarter 2016 financial results after market close on Monday, November 7, 2016.